Daurichromenic acid has attracted interest primarily for its biological activity, particularly its potent anti-HIV properties. It acts as an inhibitor of HIV-1 integrase, a key enzyme that the virus uses to integrate its genetic material into the host cell's DNA. By blocking this enzyme, the compound effectively suppresses viral replication, making it a promising candidate for the development of antiretroviral therapies. Research has also indicated anti-inflammatory and neuroprotective effects, suggesting potential use in treating neurodegenerative conditions. Additionally, it shows antimicrobial activity against certain pathogens, broadening its scope in pharmaceutical applications. Furthermore, preliminary studies have indicated anti-cancer effects at the cellular level. Most studies to date have been in vitro or preclinical, but they highlight its value as a lead compound in drug discovery.